<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150228</url>
  </required_header>
  <id_info>
    <org_study_id>A3051016</org_study_id>
    <nct_id>NCT00150228</nct_id>
  </id_info>
  <brief_title>12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation</brief_title>
  <official_title>A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing
      strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up
      of smoking status to one year from randomization was performed in a non-treatment extension
      Protocol A3051019
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-week continuous quit rate (CQR) at Weeks 4-7 and 9-12 .</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous abstinence rate from target quit date to end of treatment (Week 12)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day point prevalence of abstinence at Week 12</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cigarettes smoked per day</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urge to smoke and withdrawal symptoms assessed by Minnesota Nicotine Withdrawal Scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rewarding effects of smoking assessed by Smoking Effects Inventory</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight change from baseline</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Smoking Cessation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-526,555 (varenicline)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have smoked an average of at least ten cigarettes per day during the
             past year

          -  No period of abstinence greater than three months in the past year

        Exclusion Criteria:

          -  Subjects with history of clinically significant cardiovascular disease

          -  Subjects with uncontrolled hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albert Lea</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3051016&amp;StudyName=+12+Week+Evaluation+of+the+Safety+and+Efficacy+of+a+Flexible+Dose+of+CP%2D526%2C555+and+Placebo+for+Smoking+Cessation</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>May 31, 2007</last_update_submitted>
  <last_update_submitted_qc>May 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

